Latest News

In a recent interview, Rajesh Bhayana, M.D., discussed pertinent findings from a new study examining the use of the large language model GPT-4o in facilitating protocoling for abdominal and pelvic CT exams.

Offering a biocompatible, non-metallic alternative to metallic tumor markers, the VM1 tumor marker reportedly offers artifact-free visibility across a variety of breast imaging including mammography, ultrasound and MRI.

In what may be the largest study to assess digital breast tomosynthesis (DBT) screening of women with dense breasts, researchers noted only a 61.8 percent sensitivity for women with extremely dense breasts.

In a recent interview, Mina Makary, M.D., discussed recent research examining diversity within interventional radiology (IR), attrition rates in IR residency programs and potential strategies to bolster recruitment and retention.

After a causal mediation analysis that adjusted for breast density, researchers found that Black women had a significantly higher likelihood of high MRI-derived background parenchymal enhancement (BPE) than White women in a study involving nearly 2,500 women.

Offering compact versatility for an array of clinical settings, the ASUS Handheld Ultrasound LU800 is reportedly the first handheld device to be supported across Android, Chrome, iOS and Windows operating systems.

In a recent interview, Ron Blankstein, M.D., discussed insights from a recent consensus statement from the American College of Cardiology on AI-enabled plaque quantification with coronary computed tomography angiography (CCTA) exams, and other pertinent considerations with the emerging technology.

The AI-CVD software reportedly combines automated quantitative measurements for cardiovascular assessments such as coronary artery calcium (CAC) scoring and epicardial fat volumetry with lung attenuation and liver attenuation analysis in one CT-based AI platform.

Is the current OLA process a viable alternative for assessing our skills?

The upgraded RefleXion X2 platform offers a 20 cm field of view that may bolster visualization of moving tumors.

For patients with triple-negative breast cancer being treated with neoadjuvant chemotherapy and immunotherapy, MRI demonstrated a 94.3 percent sensitivity for predicting pathologic complete response, according to a new study.

In addition to offering a variety of AI features, the Magnetom Flow 1.5T MRI system reportedly facilitates a 56 percent reduction in annual energy consumption in comparison to previous MRI scanners.

The use of contrast-enhanced mammography in nearly 200 cases of screening recalls yielded a 96.1 percent per-breast sensitivity rate and a 99 percent negative predictive value.